CLDI · Calidi Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.59M | - | $2.36M | $2.59M | $2.42M | - | $2.15M | $3.18M | $2.74M | - |
| SG&A | $1.60M | - | $2.69M | $3.07M | $2.64M | - | $3.07M | $3.60M | $4.01M | - |
| Total Operating Expenses | $4.19M | - | $5.05M | $5.66M | $5.06M | - | $5.23M | $5.77M | $6.75M | - |
| D&A | $394.0K | - | - | - | $91.0K | - | $100.0K | $100.0K | $102.0K | - |
| Operating Income | ($4.19M) | - | ($5.05M) | ($5.66M) | ($5.06M) | - | ($5.23M) | ($5.77M) | ($6.75M) | - |
| Interest Expense | $22.5K | - | $27.0K | $40.0K | $100.0K | - | $200.0K | $200.0K | $300.0K | - |
| Income Tax | $4.0K | - | $10.0K | $4.0K | $3.0K | - | ($1.0K) | $8.0K | $4.0K | - |
| Net Income | ($4.11M) | - | ($5.15M) | ($5.71M) | ($5.06M) | - | ($5.05M) | ($5.77M) | ($7.22M) | - |
| EPS - Basic | ($0.43) | - | ($2.21) | ($1.99) | ($2.16) | - | ($7.80) | ($16.80) | ($24.00) | - |
| EPS - Diluted | ($0.43) | - | ($2.21) | ($1.99) | ($2.16) | - | ($7.80) | ($16.80) | ($24.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.85M | $5.82M | $10.59M | $5.38M | $10.78M | $9.60M | $1.90M | $800.0K | $1.20M | $2.17M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $7.35M | $6.26M | $11.03M | $6.05M | $11.49M | $10.23M | $2.22M | $1.63M | $1.94M | $4.30M |
| Total Assets | $9.59M | $8.86M | $14.03M | $9.35M | $15.06M | $14.18M | $6.66M | $6.43M | $7.41M | $10.02M |
| Current Liabilities | $3.84M | $3.94M | $5.19M | $5.35M | $5.43M | $9.50M | $11.58M | $13.05M | $14.95M | $10.23M |
| Long-term Debt | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $600.0K | $2.37M | $1.93M | $3.38M | $2.06M |
| Total Liabilities | $4.66M | $5.10M | $6.83M | $7.28M | $7.76M | $12.21M | $16.45M | $18.18M | $21.98M | $18.25M |
| Stockholders' Equity | $4.93M | $3.76M | $6.92M | $1.76M | $6.94M | $1.53M | ($11.75M) | ($11.75M) | ($14.57M) | ($8.23M) |
| Retained Earnings | ($145.73M) | ($141.62M) | ($137.56M) | ($132.42M) | ($126.70M) | ($121.72M) | ($117.62M) | ($112.56M) | ($106.80M) | ($99.57M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.12M) | - | - | - | ($7.13M) | - | - | - | ($3.83M) | - |
| Investing Cash Flow | ($5.0K) | - | - | - | ($7.0K) | - | - | - | ($5.0K) | - |
| Financing Cash Flow | $5.16M | - | - | - | $8.11M | - | - | - | $3.01M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -42.8% | - | -36.7% | -61.1% | -33.6% | - | -75.9% | -89.7% | -97.6% | - |
| Return on equity | -83.2% | - | -74.4% | -324.0% | -72.9% | - | 43.0% | 49.1% | 49.6% | - |
| Return on invested capital | -59.8% | - | -53.0% | -189.3% | -53.0% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.92 | 1.59 | 2.12 | 1.13 | 2.12 | 1.08 | 0.19 | 0.12 | 0.13 | 0.42 |
| Quick ratio | 1.92 | 1.59 | 2.12 | 1.13 | 2.12 | 1.08 | 0.19 | 0.12 | 0.13 | 0.42 |
| Cash ratio | 1.79 | 1.48 | 2.04 | 1.00 | 1.99 | 1.01 | 0.16 | 0.06 | 0.08 | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | 0.12 | 0.16 | 0.09 | 0.34 | 0.09 | 0.39 | -0.20 | -0.16 | -0.23 | -0.25 |
| Debt / Assets | 0.06 | 0.07 | 0.04 | 0.06 | 0.04 | 0.04 | 0.36 | 0.30 | 0.46 | 0.21 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -186.1x | - | -187.0x | -141.6x | -50.6x | - | -26.1x | -28.9x | -22.5x | - |
| Equity multiplier | 1.94 | 2.36 | 2.03 | 5.30 | 2.17 | 9.25 | -0.57 | -0.55 | -0.51 | -1.22 |
| Liabilities / Assets | 0.49 | 0.58 | 0.49 | 0.78 | 0.52 | 0.86 | 2.47 | 2.83 | 2.97 | 1.82 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.5x | - | 0.0x | 0.0x | 0.0x | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 17.3% | - | 3.4% | 1.9% | 25.0% | - | 27.6% | -285.9% | -232.7% | - |
| Net income growth (YoY) | 18.8% | - | -1.9% | 0.9% | 29.9% | - | -149.7% | -35.1% | -224.8% | - |
| EPS growth (YoY) | 80.1% | - | 71.7% | 88.2% | 91.0% | - | -1138.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -28.9% | 145.0% | - | - | - | - | -974.2% | 1.8% | -84.8% | -58.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Calidi Biotherapeutics against the 5 most active filers in the same SIC group.